The Patent Finder

Nammi Therapeutics, Inc.

12 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2040
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 20, 2026
    The maintenance fee for Formulated and/or co-furmulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof (US 11,679,141) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Mar 5, 2027
    The maintenance fee for Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof (US 11,744,874) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 1 fee due Apr 30, 2027
    The maintenance fee for Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof (US 11,801,304) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (US 11,833,209) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof (US 11,896,646) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 12,162,958Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNA and Ifnb) for Use in the Treatment of Cancer and Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 11,896,646Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 12,311,010Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 12,702,695Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
US 11,679,141Formulated and/or co-furmulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
US 11,801,304Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
US 11,744,874Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
US 12,059,470Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
US 12,286,403Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 11,833,209Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited